Adial Pharmaceuticals (ADIL) announced that it received notice from Nasdaq on July 14, 2025 that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2,500,000. Cary Claiborne, President and Chief Executive Officer of Adial, commented, “We’re pleased to have regained compliance with Nasdaq, a key step in reinforcing investor confidence and supporting our long-term growth strategy. This reflects our commitment to disciplined financial management as we continue advancing our pipeline and creating value for shareholders.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals Raises $3.6 Million to Meet Nasdaq Rules
- Adial Pharmaceuticals files PCT patent application for core assets
- Adial Pharmaceuticals secures U.S.-based manufacturing through agreements
- Adial Pharmaceuticals Completes $3.6M Public Offering
- Adial Pharmaceuticals prices 11.1M shares at 32.51c in public offering